Linkedin
RLS logo_header
Linkedin

TOP STORIES from the week

TEADCO Ph 1b/2 basket trial of ODM-212 + SoC initiated in patients with select advanced solid tumors

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Ph 2/3 Study in Patients with Biliary Tract Cancer

Taletrectinib (IBTROZI®) Added as Recommended Option to NCCN Guidelines for CNS Cancers

First Patient Dosed in Ph 1/2 Study of MT-304 in HER2-Positive Solid Tumors

Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination in 1L Metastatic Breast Cancer Announced 

FDA Approves Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer

FDA Accepts for Priority Review Supplemental BLA for Ziihera® (zanidatamab-hrii) Combo in 1L HER2+ Locally Advanced or Metastatic GEA

Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination in 1L Metastatic Breast Cancer Announced 

First Patient Dosed in Ph 1/2 Study of MT-304 in HER2-Positive Solid Tumors

​​Boehringer Ingelheim and Zai Lab announce collaboration on DLL3‑targeting T‑Cell Engager and ADC combination in SCLC and other Neuroendocrine Carcinomas​ 

Stay up to date with OTW

Get all oncology clinical development news in your inbox

Drug approvals

Ojemda® approved in the EU in R/R pediatric low-grade glioma regardless of BRAF alteration

ZEPZELCA + Tecentriq approved for use in Australia and Singapore as 1L maintenance treatment for adult patients with ES-SCLC

Blenrep (belantamab mafodotin) approved in China for treatment of 2L+ relapsed/refractory multiple myeloma

European Commission Approves KEYTRUDA + Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens

Regulatory news

Taletrectinib (IBTROZI®) Added as Recommended Option to NCCN Guidelines for CNS Cancers

FDA Accepts for Priority Review Supplemental BLA for Ziihera® (zanidatamab-hrii) Combo in 1L HER2+ Locally Advanced or Metastatic GEA

Type C meeting with FDA provides alignment on design of a pivotal clinical study to support approval of pelareorep in patients with unresectable metastatic SCAC

EMA application for adding new indication for Pluvicto withdrawn

Trial results

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Ph 2/3 Study in Patients with Biliary Tract Cancer

Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination in 1L Metastatic Breast Cancer Announced 

LP-300 Demonstrates 8.3-Month Median PFS in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity

Nature publishes positive pancreatic cancer Ph 1b data for NP137 

trial status

TEADCO Ph 1b/2 basket trial of ODM-212 + SoC initiated in patients with select advanced solid tumors

First Patient Dosed in Ph 1/2 Study of MT-304 in HER2-Positive Solid Tumors

First Patient Dosed in Expanded Access Program for Leronlimab in TNBC

Dose expansion in clinical study of spevatamig + chemo for treatment of biliary tract cancer

Business news

Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera

Terremoto Biosciences Closes $108 Million Series C Financing to Advance Selective AKT1-Inhibitors in Oncology

​​Boehringer Ingelheim and Zai Lab announce collaboration on DLL3‑targeting T‑Cell Engager and ADC combination in SCLC and other Neuroendocrine Carcinomas​ 

Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies

Archive

2025

2024

2023

2022

2021

2020

2019

2018